Gene Therapy, Made in India: CRISPR for Sickle Cell and a Hemophilia Cure

India crossed two thresholds in gene therapy within a year, and together they reframe what a sovereign cell-and-gene capability can look like in a low-income setting. On 20 November 2025, CSIR-IGIB launched BIRSA 101, described as India's first indigenous CRISPR-Cas9 gene therapy for sickle cell disease, with the Serum Institute of India licensed to manufacture it. Separately, a first-in-human gene therapy for severe haemophilia A, run by CMC Vellore and inStem, reported something rare in this field: a durable, curative-intent outcome, published in the New England Journal of Medicine. One programme attacks the affordability problem that has kept Western gene therapies out of reach; the other supplies the clinical durability data that de-risks the entire thesis.

The technology: editing blood stem cells outside the body

Both programmes operate on the same workhorse platform, ex-vivo modification of haematopoietic stem cells (HSCs). Clinicians harvest the patient's own CD34+ blood stem cells, modify them in the laboratory, and reinfuse them after a conditioning regimen clears space in the bone marrow. Because the edited cells are the patient's own, there is no donor-match requirement and no graft-versus-host risk. The two programmes differ in how they alter the genome.

BIRSA 101 uses CRISPR-Cas9 to edit the patient's HSCs, targeting the pathway governing the HBB mutation that causes sickle cell disease, with the aim of restoring functional haemoglobin. Mechanistically this sits in the same family as Vertex and CRISPR Therapeutics' Casgevy, the first CRISPR medicine approved anywhere, which works by reactivating fetal haemoglobin. The haemophilia A programme takes a different route: a lentiviral vector delivers a working copy of the Factor VIII (FVIII) gene into CD34+ cells, so the reinfused cells and their progeny secrete the clotting factor the patient cannot make. One is gene editing; the other is gene addition. Both are ex-vivo, autologous, and one-time in intent.

The haemophilia result that matters

The strongest data point is the haemophilia A trial at CMC Vellore's Centre for Stem Cell Research (CSCR) with inStem, funded by the Department of Biotechnology. Across five participants, the lentiviral CD34+ FVIII therapy produced an annualised bleeding rate of zero over roughly 81 cumulative patient-months of follow-up. That outcome was published in NEJM.

For a field that has been burned repeatedly by therapies that work briefly and then fade, a sustained zero bleeding rate is the result clinicians and investors actually care about. Severe haemophilia A is otherwise managed with lifelong, expensive FVIII prophylaxis or newer antibody therapies; a one-time treatment that eliminates spontaneous bleeds changes the lifetime cost equation entirely. Five patients is a small cohort and longer follow-up is needed to confirm durability and rule out late safety signals, including the integration risks inherent to lentiviral vectors. But durable curative-intent data, generated and published from an Indian academic-medical centre, is precisely the evidence that converts a speculative national ambition into an investable platform.

BIRSA 101 and the affordability argument

The economic case for BIRSA 101 is built on the Casgevy comparison. Casgevy is transformative and effectively unaffordable in most of the world, with a price tag the Indian programme's backers put at roughly ₹15 to 20 crore per patient. BIRSA 101 is being pitched as the most affordable CRISPR therapy in the world, a claim that rests on indigenous development at CSIR-IGIB and domestic manufacturing through the Serum Institute, the world's largest vaccine maker by volume. Serum's involvement is the part investors should weigh most heavily. The hard problem in autologous cell therapy is not the edit; it is reproducible, GMP-grade manufacturing at scale and acceptable cost. Licensing to an organisation with Serum's process-engineering and scale-up capability is what could make an order-of-magnitude price reduction credible rather than aspirational.

The therapy's trials are in advanced stages, with CDSCO approval anticipated in 2026-27. That timeline should be read as a target, not a certainty; regulatory review of a first-in-class indigenous gene therapy can move slowly.

The addressable population and policy alignment

What gives the Indian thesis its distinctive shape is demand. Sickle cell disease is not a rare condition here. An estimated 1.5 to 2 crore Indians are affected, concentrated in tribal and central-belt populations, and the government has made elimination a stated objective through the National Sickle Cell Anaemia Elimination Mission. BIRSA 101 is explicitly aligned with that programme.

This inverts the usual gene-therapy commercial logic. In the West, these therapies are priced as ultra-rare-disease products with tiny patient pools and stratospheric per-unit prices. In India, the same disease is a public-health-scale problem with a national mission and political will behind it. A therapy that is both clinically curative and affordable at population scale has a fundamentally different total addressable market, one defined by a government elimination target rather than a niche specialty market. The same dynamic applies, at smaller scale, to haemophilia, where the addressable population is large enough to justify domestic manufacturing.

Why this de-risks India's gene-therapy thesis

The investment case for Indian gene therapy has long rested on cost arbitrage, the same argument that built the country's generics and vaccine industries. The 2025-26 milestones add two things that arbitrage alone never could. First, the haemophilia NEJM publication supplies durable efficacy data from Indian institutions, addressing the central scientific risk that ex-vivo gene therapies might not last. Second, the Serum Institute manufacturing licence for BIRSA 101 attaches a world-scale industrial partner to the central commercial risk, reproducible manufacturing economics.

The caveats are real and should not be glossed. Patient numbers in both programmes remain small. BIRSA 101 is not yet CDSCO-approved. Conditioning regimens carry their own toxicity, vector-integration safety requires long surveillance, and the delivery infrastructure for autologous therapy, apheresis, GMP labs, transplant-capable centres, is thin outside a handful of cities. Reimbursement, as with CAR-T, is unresolved; a population-scale cure still needs a payer.

The direction of travel, though, is unambiguous. A domestic CRISPR therapy licensed to the world's largest vaccine manufacturer, and an academic lentiviral programme delivering zero bleeding rates in NEJM, are not isolated proofs of concept. They are the two halves of a maturing platform: indigenous editing chemistry plus industrial-scale manufacturing, pointed at diseases that afflict millions of Indians rather than a few thousand. If the regulatory and reimbursement pieces fall into place over the next two to three years, India will have demonstrated something no other country has, that frontier gene therapy can be deployed as public-health infrastructure, not boutique medicine.